scholarly journals Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part I

2015 ◽  
Vol 6 (2) ◽  
pp. 69-80
Author(s):  
M. G Bubnova
Keyword(s):  
Angiotensin Ii ◽  
Clinical Characteristics ◽  
Antihypertensive Drugs ◽  
Antihypertensive Efficacy ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Blockers ◽  
Azilsartan Medoxomil ◽  
Term Management

This article deals withthe overview of the pharmacological characteristics of one class of antihypertensive drugs - angiotensin II receptor antagonists (ARA II) and new member of this class - azilsartan medoxomil (Edarbi®).We have analyzed the antihypertensive efficacy of different ARA, as well as azilsartan medoxomil efficacyin case of monotherapy and in comparison with other ARA and angiotensin-converting enzyme inhibitorsamong different groups of patients.The article describes the pleiotropic effects of azilsartan medoxomil, discovered nowadays.

scholarly journals Modern approaches to the treatment and long-term management of arterial hypertension in clinical practice. Pharmacological and clinical characteristics of angiotensin II receptor blockers: focus on azilsartan medoxomil. Part II

2015 ◽  
Vol 6 (3) ◽  
pp. 58-69
Author(s):  
M. G Bubnova
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Cardiovascular Events ◽  
Clinical Characteristics ◽  
Angiotensin Ii Receptor ◽  
Treatment Of Hypertension ◽  
Receptor Blockers ◽  
Azilsartan Medoxomil ◽  
Term Management

The article discusses the problem of the use for the treatment of hypertension combination therapy. Advantages of application as a component of chlorthalidone therapy are discussed. Proofs of its effectiveness in lowering both blood pressure and risk of cardiovascular events compared with hydrochlorothiazide are stated. Anti-hypertensive effectiveness of one of the last appeared on the pharmacological market of receptor-blockers like angiotensin II azilsartan medoxomil in combination with chlorthalidone is discussed as well.

The Impact of Angiotensin-II Receptor Blockers on Cardiovascular Events in Hypertensive Patients – Evidence from Real-life Databases

2010 ◽  
Vol 6 (3) ◽  
pp. 33
Author(s):  
Robert J Petrella ◽  
Keyword(s):  
Angiotensin Ii ◽  
Antihypertensive Drugs ◽  
Real Life ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Real World Setting ◽  
Actual Experience ◽  
Receptor Blockers ◽  
Randomised Controlled ◽  
The Impact

It is widely recognised that hypertension is a major risk factor for the development of future cardiovascular (CV) events, which in turn are a major cause of morbidity and mortality. Blood pressure (BP) control with antihypertensive drugs has been shown to reduce the risk of CV events. Angiotensin-II receptor blockers (ARBs) are one such class of antihypertensive drugs and randomised controlled trials (RCTs) have shown ARB-based therapies to have effective BP-lowering properties. However, data obtained under these tightly controlled settings do not necessarily reflect actual experience in clinical practice. Real-life databases may offer alternative information that reflects an uncontrolled real-world setting and complements and expands on the findings of clinical trials. Recent analyses of practice-based real-life databases have shown ARB-based therapies to be associated with better persistence and adherence rates and with superior BP control than non-ARB-based therapies. Analyses of real-life databases also suggest that ARB-based therapies may be associated with a lower risk of CV events than other antihypertensive-drug-based therapies.

scholarly journals Long-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
K. Wegleiter ◽  
M. Waltner-Romen ◽  
R. Trawoeger ◽  
U. Kiechl-Kohlendorfer ◽  
E. Griesmaier
Keyword(s):  
Angiotensin Ii ◽  
Receptor Antagonist ◽  
Neonatal Period ◽  
Clinical Symptoms ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Angiotensin Ii Receptor Antagonist ◽  
Receptor Antagonists

Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although clinical symptoms in the neonatal period are well described, few reports address long-term follow-up after fetal exposure to angiotensin II receptor antagonists. We here report on a patient who was unwittingly exposed to olmesartan medoxomil during pregnancy. After birth, the neonate presented with mild clinical symptoms, mainly affecting the kidneys. However, neurodevelopmental follow-up revealed a delay in motor development with muscular hypotonia and failure to thrive at age 2 years. This case highlights the fact that, despite not causing neurological symptoms in the neonatal period, fetal angiotensin II receptor antagonist exposure during pregnancy might lead to neurodevelopmental impairment in later life.

New Therapeutic Agents in the Management of Hypertension: Angiotensin II-Receptor Antagonists and Renin Inhibitors

1993 ◽  
Vol 27 (12) ◽  
pp. 1495-1503 ◽  
Author(s):  
Edward F. Foote ◽  
Charles E. Halstenson
Keyword(s):  
Clinical Trials ◽  
Angiotensin Ii ◽  
Ace Inhibitors ◽  
English Language ◽  
Antihypertensive Drugs ◽  
Pharmacokinetic Studies ◽  
Angiotensin Ii Receptor ◽  
Angiotensin Ii Receptor Antagonists ◽  
Receptor Antagonists ◽  
Renin Inhibitors

OBJECTIVE: To review the chemistry, pharmacokinetics, and clinical trials of two new classes of antihypertensive drugs, angiotensin II-receptor antagonists and renin inhibitors. DATA SOURCES: Primary literature on angiotensin II-receptor antagonists and renin inhibitors was identified through a comprehensive medical literature search from 1961 through 1993. This search included journal articles, abstracts, and reports of both animal and human research published in the English language. Indexing terms included renin-angiotensin aldosterone system, renin inhibitors, angiotensin II antagonists, DuP 753, losartan, MK954, A-64662, and Ro 42–5892. STUDY SELECTIONS: Emphasis was placed on clinical and pharmacokinetic studies in humans for drugs that are currently in Phase I—III research protocols in the US. DATA EXTRACTION: All available data from human studies were reviewed. DATA SYNTHESIS: Angiotensin II-receptor antagonists and renin inhibitors may be effective antihypertensives with few adverse effects noted in the small studies completed. Their potential advantage over angiotensin-converting enzyme (ACE) inhibitors includes a possible smaller adverse effect profile. In the past, the clinical utility of angiotensin II-receptor antagonists and renin inhibitors has been limited because of poor oral bioavailability, although newer agents are more readily bioavailable. CONCLUSIONS: Angiotensin II-receptor antagonists and renin inhibitors may be the next new classes of antihypertensives marketed. However, definitive conclusions about their roles in the management of hypertension are not possible until larger clinical trials assessing their efficacy and safety and comparing them with ACE inhibitors are completed.

Sign in / Sign up

Export Citation Format

Share Document